China’s CanSino cuts ties with Brazilian companies and suspends vaccine licenses



Brasilia — Brazilian health regulator Anvisa said CanSino Biologics Inc in China after the institute cut off its ties with Brazilian representatives. Canceled the request for an emergency use authorization for the COVID-19 vaccine developed by.

The move follows a wave of scrutiny of vaccine contracts in Brazil negotiated by brokers, a common local practice.

Federal prosecutors and senator investigators are investigating India’s vaccine arrangements, and one senator accused President Jair Bolsonaro of closing his eyes on allegations of fraud on Monday. The president and businesses involved in these talks have denied any misconduct.

CanSino and his former Brazil national team, Belcher Pharmaceuticals, Inc., Did not immediately respond to emails requesting comments about the end of their relationship.

According to a document seen by Reuters, the Brazilian Ministry of Health signed an agreement with Belcher on June 4 to purchase 60 million CanSino single-dose vaccines for delivery in late 2021.

According to the document, the price of a vaccine under the Convidecia brand, developed by CanSino in collaboration with Chinese military-related research institutes, was $ 17 each time.

Ambisa said in a statement that the board unanimously canceled the emergency use request late Monday after receiving a notification from CanSino by email that Belcher was no longer the official representative of Brazil. Stated.

CanSino has requested a change of Brazilian representative. Anvisa added that the new representative will need to reapply for an emergency use authorization.

Anthony Boador and Eduardo Simoes

Posted on